This phase 1–2, randomised, double-blind, placebo-controlled trial enrolled 130 patients aged 18 or older with confirmed ...

Both drugs are classified as guanylate cyclase-C agonists. Linzess capsules and Trulance tablets are available only as ...

After a quiet few years Merck has returned to the category with soluble guanylate cyclase (sGC) stimulators Adempas (riociguat) and Verquvo (vericiguat) – partnered with Bayer – for PAH and ...

These cyclases represent a new guanylate cyclase subfamily, termed ROS-GC, which distinguishes itself from the peptide receptor guanylate cyclase family that it is not extracellularly regulated. It is ...

The soluble guanylate cyclase activator runcaciguat significantly improved albuminuria in patients with CKD on top of RAS inhibitor and SGLT2 inhibitor treatment. Runcaciguat, an oral soluble ...

Linaclotide, a guanylate cyclase C receptor agonist, has shown promising efficacy as a treatment for chronic constipation in a phase IIb, double-blinded, placebo-controlled, dose-ranging trial.

Pulmovant is tasked with taking forward mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator, which is being developed to treat pulmonary hypertension associated with interstitial ...

Owing to these mechanisms of action, Ibsrela is a first-in-class IBS-C med, with the other four approved therapies classified as guanylate cyclase-C [GCC] agonists. The latter drugs promote the ...

NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular smooth muscle and consequent ...

Mosliciguat is under clinical development by Bayer and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase I drugs for Kidney Disease (Nephropathy) have a 71% phase ...

Stephen, R., Palczewski, K., Sousa, M.C. (2008) Ca2+-dependent regulation of phototransduction. Photochem. And Photobiol. 84. 903-910 Stephen, R. (2008) Structural ...